KRAS and familial pancreatic carcinoma: Thus, these results suggest that pancreatic cancer cells carrying both KRAS and p53 mutations are vulnerable to BSO and DPI combinatory inhibition, and the cytotoxic effect of BSO and DPI was mainly triggered by a redox-mediated mechanism.